Full text
Earnings transcript
Read the complete earnings call transcript.
AGEN
Agenus Inc.
$3.33
-0.07
(-2.06%)
[ms_data_label text=’Delayed data’]
| Exchange: | NASDAQ |
| Market Cap: | 127.867M |
| Shares Outstanding: | 8.625M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Garo H. Armen | |||||
| Full Time Employees: | 316 | |||||
| Address: |
| |||||
| Website: | https://www.agenusbio.com |
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 156,314 | 103,463 | 114,196 |
| Gross Profit | -81,366 | -52,551 | 103,175 |
| EBITDA | -145,924 | -101,302 | -10,557 |
| Operating Income | -159,549 | -120,475 | -20,556 |
| Net Income | -245,761 | -227,212 | 115 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 313,913 | 226,271 | 226,798 |
| Total Liabilities | 462,295 | 532,695 | 504,659 |
| Total Stockholders Equity | -160,331 | -326,380 | -271,111 |
| Total Debt | 78,012 | 94,870 | 334,899 |
| Cash and Cash Equivalents | 76,110 | 40,437 | 2,998 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -224,202 | -158,315 | -158,315 |
| Capital Expenditure | -9,954 | -576 | -576 |
| Free Cash Flow | -234,156 | -158,891 | -158,891 |
| Net Income | -245,761 | -232,271 | -232,271 |
| Net Change in Cash | -101,564 | -35,708 | -35,708 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 169,752.128 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 175,247.871 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 172,500 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | -100,136.903 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | -96,996.627 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | -98,566.766 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | -3,338.533 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | -3,202.946 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | -3,270.740 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 90,710.462 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 93,647.222 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 92,178.842 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | -0.110 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | -0.110 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | -0.110 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 1 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about AGEN valuation
Is Agenus Inc. (AGEN) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Agenus Inc. (AGEN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is AGEN a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether AGEN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is AGEN’s P/E ratio?
You can see AGEN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for AGEN?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is AGEN a good long-term investment?
Whether AGEN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
AGEN
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
[ms_data_label text="Daily snapshot"]
-2.06
Trading Metrics:
| Open: | [ms_cell_or_dash table='trading_quote' column='open'] | Previous Close: | [ms_cell_or_dash table='trading_quote' column='previousClose'] | |
| Day Low: | [ms_cell_or_dash table='trading_quote' column='dayLow'] | Day High: | [ms_cell_or_dash table='trading_quote' column='dayHigh'] | |
| Year Low: | 1.38 | Year High: | 7.34 | |
| Price Avg 50: | 3.21 | Price Avg 200: | 4.14 | |
| Volume: | 480553 | Average Volume: | 707018 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
